Sorafenib was the first systemic therapy to be approved for the treatment of Liver cancer (Hepatocellular Carcinoma – HCC), but unfortunately the benefits could not reach patients as it was priced beyond the reach of most of the Indians. NATCO saw the plight of the suffering and responded by making the product available through compulsory license.
Today thousands of Liver and Kidney cancer patients are able to realise the benefits of Sorafenib through the efforts taken by NATCO to obtain compulsory license. Sorafenat has also helped to redefine the boundaries of Intellectual Property Rights in the context of life threatening diseases. Sorafenat is made available free to more than 600 poor and deserving patients every year.
